home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

5th Annual Peptides Congress, 16 – 17 April 2018, London, UK

  September 11, 2017  
Oxford Global Conferences, Novotel London West
16th - 17th April 2018

Oxford Global Conferences are proud to present our 5th Annual Peptides Congress, 16 – 17 April 2018, London, UK, collocated with our 11th Annual Proteins & Antibodies Congress and 5th Annual Biosimilars & Biobetters Congress. Over 450 peptides, proteins and antibodies attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions will have the opportunity to discuss over 25 presentations and case studies focused on the key advancements in peptides technologies, peptide therapeutics as well as chemistry and delivery.

View Agenda: http://bit.ly/2xsqcZ6

3 interactive streams:

·         Peptide Research, Chemistry and Analytical Technologies

·         Peptide Therapeutics

·         Peptide Discovery, Manufacturing and Delivery.

Free Live Webinar:

From Peptide Discovery to Phase 3 – A Zealand Perspective
Hosted by Andy Parker, Senior Vice President & Chief Scientific Officer, Zealand Pharma
Register for Free
Today: http://bit.ly/2uQ2XuA

Free Webinar Recording:

Improved Non-Invasive Routes of Administration of Peptides
Hosted by Joël Richard, Senior Vice President, Peptides, Head of CMC Development Dreux Site, Ipsen
Download for Free Today:

Organized by: Oxford Global Conferences
Invited Speakers:

Les Miranda, Executive Director Research

Marian Gindy, Director Sterile Formulation Sciences

Alan Mathiowetz, Director

Todd Page, Director of Toxicology
Eli Lilly

Vivian Lindo, Associate Director Product Characterisation

Natia Tsomaia, Associate Director

Magnus Jaderberg, Chief Medical Officer

Andy Parker, Senior Vice President and Chief Scientific Officer
Zealand Pharma

Jesse Dong, Vice President Peptide Chemistry
Neon Therapeutics

Daniel O’Brecht, Chief Scientific Officer

Mette Svendgaard, Director Pharmaceutical Development
Zealand Pharma

Marc Thommen, Head of Chemistry

Frank Thielmann, PMO and Operational Excellence Platform Leader

Stephen Buckley, Head of Discovery ADME
Novo Nordisk

Mathias Schaffrath, Group Head Chromatography

Lukas Leder, Lab Head Peptide Discovery Platform

Claudio Mapelli, Principal Scientist

William Drury, Associate Principal Scientist

Mohamed ElSayed, Senior Research Advisor & Program Leader
Eli Lilly

Andreas Evers, Senior Scientist

Elizabeth Pierson, Senior Scientist

Thomas De Vijlder, Senior Scientist

Ying-Kai Wang, Senior Research Investigator II
Bristol Myers Squibb

Liuhong Chen, Discovery Biology Team Leader
Bicycle Therapeutics Ltd

Cedric Fiez-Vandal, Senior Scientist
Heptares Therapeutics

Johannes Urban, Senior Scientist Technology Development

Hao Luo, Associate Principal Scientist

David Craik, Professor & Group Leader, Chemistry and Structural Biology
University of Queensland

Michal Bassani-Sternberg, Head of Immunopeptidomics Unit, Department of Oncology
University Hospital of Lausanne (CHUV), Switzerland and the Ludwig Institute for Cancer Research

Steven Ballet, Professor
Free University Brussels

Mark Howarth, Associate Professor
University of Oxford

Deadline for Abstracts: 16/04/17

For further information regarding prices and possible discounts, please contact Guillaume Alonso on g.alonso@oxfordglobal.co.uk or call +44 (0)1865 248 455.

E-mail: g.alonso@oxfordglobal.co.uk
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.